Vir Biotechnology, Inc. (VIR) stock
VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/3021% below fair value
$9.96−2.16 (-17.82%)
Close on Nov 13, 2026Market cap $1.69BP/E –Yield –
Vir Biotechnology statistics
79 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Feb 22, 2027 (estimated, after the close)
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 13, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 1.93
- 2.22
Enterprise valuationIndustry
- EV / Sales
- 4.06
- 2.57
Share statisticsIndustry
- Shares Change (YoY)
- 13.2%
- 10.8%
- Shares Change (QoQ)
- 0.14%
- 0.50%
- Float
- 140M
- 49M
- Shares Held by Insiders
- 17.0%
- 11.7%
- Shares Held by Institutions
- 86.6%
- 56.4%
Short sellingIndustry
- Short Interest
- 17M
- –
- Short Interest Change
- 3.93%
- -0.80%
- Short % of Float
- 12.0%
- 9.01%
- Short % of Shares Outstanding
- 9.97%
- 6.30%
- Days to Cover
- 11.86
- 5.15
Stock price statisticsIndustry
- 52-Week High
- $14.38
- –
- 52-Week Low
- $5.32
- –
- 20-Day Moving Average
- $11.47
- –
- 50-Day Moving Average
- $11.15
- –
- 200-Day Moving Average
- $9.76
- –
- Average True Range (14)
- $0.92
- –
- Price Change (1 Week)
- -18.4%
- -1.15%
- Price Change (1 Month)
- -4.87%
- -4.87%
- Price Change (3 Months)
- 6.07%
- -21.0%
- Price Change (6 Months)
- 13.3%
- -20.6%
- Price Change (YTD)
- 65.2%
- -23.6%
- Price Change (1 Year)
- 74.4%
- -22.4%
- Price Change (3 Years)
- 1.01%
- -29.5%
- Price Change (5 Years)
- -69.9%
- -77.9%
- Average Volume (10 Days)
- 4M
- –
- Average Volume (20 Days)
- 3M
- –
- Average Volume (90 Days)
- 2M
- –
- Relative Volume
- 8.71
- 0.70
- Relative Strength Index (14)
- 40.5
- 43.4
- Volatility (1 Year)
- 68.4%
- 80.1%
- Beta (5 Years)
- 0.72
- 1.07
MarginsIndustry
- Pretax Margin
- -61.0%
- -11.6%
- EBITDA Margin
- -66.1%
- -27.7%
- FCF Margin
- -46.8%
- -9.56%
Returns on capitalIndustry
- Return on Equity (ROE)
- -21.8%
- -49.9%
- Return on Assets (ROA)
- -17.3%
- -40.6%
- Return on Invested Capital (ROIC)
- -45.2%
- -32.9%
- Return on Capital Employed (ROCE)
- -20.5%
- -37.9%
Financial positionIndustry
- Current Ratio
- 6.30
- 3.30
- Quick Ratio
- 5.64
- 2.39
GrowthIndustry
- Revenue Growth (YoY)
- 1696.0%
- 6.82%
- Revenue Growth (3Y CAGR)
- -65.1%
- 2.25%
- Revenue Growth (5Y CAGR)
- -2.14%
- 6.41%
EfficiencyIndustry
- Asset Turnover
- 0.28
- 0.40
- Revenue Per Employee
- $825.07K
- $429.29K
- Profits Per Employee
- -$503.52K
- -$689.41K
- Employee Count
- 367
- 74
- WACC
- 8.68%
- 10.2%
Income statement (TTM)Industry
- Pretax Income
- -$184.72M
- -$12.95M
Balance sheetIndustry
- Net Cash (Debt)
- $454.64M
- $17.76M
- Net Cash Per Share
- $2.69
- $0.80
- Equity (Book Value)
- $896.04M
- $53.89M
- Book Value Per Share
- $5.30
- $1.50
- Tangible Book Value
- $871.47M
- $27.13M
- Working Capital
- $427.61M
- $79.99M
Cash flow (TTM)Industry
- Capital Expenditures
- -$804.00K
- -$1.00M
- FCF Per Share
- -$0.84
- -$0.42
Dividends and yieldsIndustry
- Earnings Yield
- -11.0%
- -21.8%
- FCF Yield
- -8.41%
- -9.44%
Taxes and interestIndustry
- Income Tax
- $69.00K
- $73.00K
Scores and fair valueIndustry
- Altman Z-Score
- 3.11
- 0.23
- Piotroski F-Score
- 3
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | VIR | S&P 500 | Difference | VIR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -6.1% | -3.0% | −3.1 pts | ||
| 3 months | +10.7% | -2.8% | +13.4 pts | ||
| Year to date | +65.2% | +11.5% | +53.7 pts | ||
| 1 year | +82.1% | +13.5% | +68.6 pts | ||
| 3 years | +8.5% | +77.7% | −69.2 pts | +2.8% | +21.1% |
| 5 years | -69.9% | +72.6% | −142.5 pts | -21.4% | +11.5% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
17M VIR shares were sold short on Oct 30, 2026, up 3.9% from the previous report, or 12.01% of the shares available to trade. At recent volumes it would take 11.9 days to buy them back. Over the last 20 sessions, 52.4% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 16,874,443 | +3.9% | 1,423,351 | 11.9 |
| Oct 15, 2026 | 16,236,717 | +8.4% | 2,347,735 | 6.9 |
| Sep 30, 2026 | 14,980,532 | -23.8% | 2,138,348 | 7.0 |
| Sep 15, 2026 | 19,660,671 | -7.9% | 2,075,573 | 9.5 |
| Aug 31, 2026 | 21,341,508 | +8.9% | 1,921,958 | 11.1 |
| Aug 14, 2026 | 19,595,909 | +2.9% | 1,438,318 | 13.6 |
| Jul 31, 2026 | 19,040,209 | +3.2% | 1,556,119 | 12.2 |
| Jul 15, 2026 | 18,452,974 | -3.9% | 1,541,749 | 12.0 |
| Jun 30, 2026 | 19,192,724 | +6.1% | 3,209,850 | 6.0 |
| Jun 15, 2026 | 18,082,921 | -1.3% | 1,515,506 | 11.9 |
| May 29, 2026 | 18,316,762 | +8.8% | 1,694,464 | 10.8 |
| May 15, 2026 | 16,833,002 | +4.4% | 1,537,245 | 10.9 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?